PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents

PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents - PRIMA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54892

Enrollment

350

Registered

2021-02-11

Start date

2020-06-17

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid malgnancies solid tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Histological or cytological proven solid tumor • Age >=18 years • Written informed consent • Performance score: WHO 0-2 at the time of study entry • Planned treatment with (intravenous) immune modulating agents for any type of cancer according to standard of care.

Exclusion criteria

Exclusion criteria: • Unable to draw blood for study purposes (e.g. severe anemia Hb

Design outcomes

Primary

Measure	Time frame
The primary study endpoint is the evaluation of the interaction between genetic and immunological characteristics of a patients tumor and the IMA prescribed.	—

Secondary

Measure	Time frame
Secondary endpoint includes the determination of immunological and genetic differences in tumor biopsies of patients responding and patients not responding to IMA.	—

Countries

Netherlands

Outcome results